Zimmer Biomet Holdings, Inc. $ZBH Stock Holdings Cut by Douglas Lane & Associates LLC

Key Points

• Douglas Lane & Associates LLC has reduced its stake in Zimmer Biomet Holdings, Inc. by 5.0% during the second quarter, now owning 402,349 shares worth approximately $36.7 million.
• Zimmer Biomet reported $2.07 earnings per share for the latest quarter, exceeding expectations, with revenue rising 7.0% year-over-year to $2.08 billion.
• The company announced a quarterly $0.24 dividend, which will be paid on October 31st, indicating an annualized yield of 0.9% and a payout ratio of 23.36%.

Douglas Lane & Associates LLC cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 402,349 shares of the medical equipment provider's stock after selling 20,954 shares during the quarter. Douglas Lane & Associates LLC owned 0.20% of Zimmer Biomet worth $36,698,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ZBH. Brighton Jones LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth $204,000. Focus Partners Wealth boosted its stake in shares of Zimmer Biomet by 16.2% during the 4th quarter. Focus Partners Wealth now owns 16,528 shares of the medical equipment provider's stock worth $1,760,000 after acquiring an additional 2,303 shares in the last quarter. OMERS ADMINISTRATION Corp boosted its stake in shares of Zimmer Biomet by 19.9% during the 4th quarter. OMERS ADMINISTRATION Corp now owns 8,684 shares of the medical equipment provider's stock worth $917,000 after acquiring an additional 1,443 shares in the last quarter. Nomura Holdings Inc. acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $693,000. Finally, Mufg Securities Americas Inc. acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $310,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

NYSE ZBH opened at $103.15 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72. The stock's 50-day moving average is $99.46 and its two-hundred day moving average is $99.55. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a market cap of $20.43 billion, a P/E ratio of 25.10, a price-to-earnings-growth ratio of 2.40 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period last year, the company earned $2.01 earnings per share. The business's revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet's payout ratio is presently 23.36%.

Analysts Set New Price Targets

Several brokerages have recently commented on ZBH. Roth Capital reaffirmed a "buy" rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. UBS Group raised their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Raymond James Financial raised their target price on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Royal Bank Of Canada raised their target price on Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Evercore ISI reduced their price objective on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and an average target price of $111.00.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.39% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.